Preoperative CA-125 levels in 123 patients b with borderline ovarian tumors a retrospective analysis and review of the literature

International Journal of Gynecological Cancer

Volumn 19, Issue 8, 2009, Pages 1335-1338

  Kolwijck, Eva ^a   Thomas, Chris M G ^a   Bulten, Johan ^a   Massuger, Leon F A G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Borderline; CA 125; Low malignant potential; Ovarian cancer; Stage I

Indexed keywords

CA 125 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 73349133314     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a83e04     Document Type: Article

References (25)

1. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50:1-7.
2. Leake JF, Currie JL, Rosenshein NB, et al. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol. 1992;47:150-158.
3. Van Calster B, Timmerman D, Bourne T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst. 2007;99: 1706-1714.
4. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922-929.
5. Andersen ES, Knudsen A, Rix P, et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol. 2003;90:109-112.
6. Bailey J, Tailor A, Naik R, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer. 2006;16:30-34.
7. Gotlieb WH, Soriano D, Achiron R, et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obstet Gynecol. 2000;183:541-546.
8. Ayhan A, Guven S, Guven ES, et al. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Acta Obstet Gynecol Scand. 2007;86:484-490.
9. Zanetta G, Rota S, Lissoni A, et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001;81:63-66.
10. Engelen MJ, de Bruijn HW, Hollema H, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-29 as tumor markers in borderline ovarian tumors. Gynecol Oncol. 2000;78:16-20.
11. Tamakoshi K, Kikkawa F, Shibata K, et al. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol. 1996;62:67-72.
12. Rice LW, Lage JM, Berkowitz RS, et al. Preoperative serum CA-125 levels in borderline tumors of the ovary. Gynecol Oncol. 1992;46: 226-229.
13. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263-264.
14. Servov SF, Scully RE, Sobin LH. International Histologic Classification of Tumors. No.9: Histological Typing of Ovarian Tumors. Geneva: World Health Organization; 1973.
15. Bast RC Jr, Klug TL, St JE, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
16. Makar AP, Kristensen GB, Kaern J, et al. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79:1002-1010.
17. Hogdall EV, Christensen L, Kjaer SK, et al. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From the Danish BMALOVA[ Ovarian Cancer Study. Gynecol Oncol. 2007;104:508-515.
18. Koper NP, Thomas CM, Massuger LF, et al. Comparison of four Fsecond generation immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis. Eur J Clin Chem Clin Biochem. 1997;35:617-623.
19. Yedema KA, Thomas CM, Segers MF, et al. Comparison of five immunoassay procedures for the ovarian carcinomaYassociated antigenic determinant CA 125 in serum. Eur J Obstet Gynecol Reprod Biol. 1992;47:245-252.
20. Wong HF, Low JJ, Chua Y, et al. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer. 2007;17:342-349.
21. Akeson M, Zetterqvist BM, Dahllof K, et al. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Int J Gynecol Cancer. 2008;18:453-459.
22. Cusido M, Balaguero L, Hernandez G, et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol Oncol. 2007;104: 617-622.
23. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
24. Paramasivam S, Tripcony L, Crandon A, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23:5938-5942.
25. Petri AL, Hogdall E, Christensen IJ, et al. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS. 2006;114:359-363.